Study identifier:D1060C00001
ClinicalTrials.gov identifier:NCT00910728
EudraCT identifier:N/A
CTIS identifier:N/A
A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
Primary Myelofibrosis (PMF)
Phase 1
No
AZD1480
All
65
Interventional
25 Years - 99 Years
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verified 01 Mar 2017 by AstraZeneca
AstraZeneca
University of Texas, New York City Hoffman Center, Institut Gustave Roussy
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD1480 | Drug: AZD1480 Oral capsule 2.5 mg, 10 mg and 40 mg |